<DOC>
	<DOCNO>NCT00055822</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Oblimersen may increase effectiveness chemotherapy make tumor cell sensitive drug . PURPOSE : Phase I/II trial study effectiveness combine oxaliplatin , fluorouracil , leucovorin oblimersen treat patient unresectable , metastatic , recurrent colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Oblimersen Treating Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose oblimersen administer oxaliplatin , fluorouracil , leucovorin calcium patient advance colorectal cancer . - Determine quantitative qualitative toxic effect regimen patient . - Determine antitumor activity regimen patient . - Determine plasma pharmacokinetics oblimersen oxaliplatin patient treat regimen . - Determine relevant predictive biomarkers response patient treat regimen . OUTLINE : This open-label , phase I , dose-escalation study oblimersen follow non-randomized , phase II study . - Phase I : Patients receive oblimersen IV continuously day 1-5 15-19 ; leucovorin calcium IV 2 hour fluorouracil IV 22 hour day 6 , 7 , 20 , 21 ; oxaliplatin IV 2 hour day 6 20 . Cohorts 3-6 patient receive escalate dos oblimersen maximum tolerate dose ( MTD ) determine . The MTD define high dose 1 6 patient experience dose-limiting toxicity . - Phase II : Up 35 additional patient treat phase I , oblimersen MTD . In phase , course repeat every 28 day absence disease progression unacceptable toxicity . Patients follow 30 day . PROJECTED ACCRUAL : A total 6-53 patient ( 6-18 patient phase I 12-35 patient phase II ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma colon rectum Unresectable , metastatic , recurrent disease Measurable evaluable disease ( phase I ) Measurable disease ( phase II ) No know brain metastasis Patients previously treat brain metastasis currently receive steroid stable CT scan MRI eligible PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic Bilirubin great 1.5 mg/dL AST/ALT great 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) INR great 1.5 time ULN ( unless currently receive anticoagulant therapy ) PT/PTT great 1.5 time ULN ( unless currently receive anticoagulant therapy ) Renal Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction compound similar chemical biologic composition fluorouracil oxaliplatin No concurrent uncontrolled medical condition would preclude study participation No ongoing active infection No psychiatric illness social situation would preclude study compliance No known history degenerative facet disease prior fluorouracil therapy No HIVpositive patient receive combination antiretroviral therapy PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent epoetin alfa course 1 No concurrent routine filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent immunotherapy Chemotherapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior oxaliplatin No concurrent chemotherapy Endocrine therapy See Disease Characteristics Radiotherapy At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery Not specify Other No prior oblimersen No concurrent investigational agent No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>